Sanofi SA SNY announced the withdrawal of its regulatory application in Europe for Dupixent (dupilumab) to treat adults with ...

Dupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.

Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP ...

Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...

For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according to a study presented at CHEST 2024, the ...

Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease Dupixent ...

Research presented at the European Academy of Allergy and Clinical Immunology Annual Congress show the safety and efficacy of dupilumab across several progressive diseases with underlying type 2 ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...